43. The compound according to any of claims 1-41, wherein R^(A) is (C₁-C₆)alkyl, halogen, (C₁-C₆)alkyl-OR^(A1), or —COOR^(A1), wherein R^(A1) is hydrogen or (C₁-C₆)alkyl, or two R^(A1) together with N-atom to which they are attached form a morpholinyl.
44. The compound according to any of claims 1-43, wherein Z is CH₂, C(H)R^(A), C(R^(A))₂, or O; m is 0 or 2; provided that when m is 0, Z is CH₂, C(H)R^(A) or C(R^(A))₂, and when m is 2, Z is O.
45. The compound according to claim 1, which is

or a pharmaceutically acceptable salt thereof.
46. A compound, which is:

or a pharmaceutically acceptable salt thereof.
47. The compound according to any one of claims 1-46, which is inform of a pharmaceutically acceptable salt.
48. The compound according to any one of claims 1-46, which is inform of a zinc (Zn²⁺) salt.
49. The compound according to claim 48, wherein the zinc salt is ZnCl, ZnBr, ZnI₂, Zn(NO₃)₂, ZnSO₄, Zn₃(PO₄)₂, or Zn(OH)₂.
50. The compound according to claim 48 or 49, wherein the compound is complexed with Zn²⁺ in a 1:1 stoichiometry.
51. The compound according to claim 48 or 49, wherein the compound is complexed with Zn²⁺ in a 2:1 stoichiometry.
52. The compound according to claim 48 or 49, wherein the compound is complexed with Zn²⁺ in a 3:1 stoichiometry.
53. The compound according to any one of claims 1-46, which is in form of a sodium (Na⁺), potassium (K⁺), calcium (Ca²⁺), or magnesium (Mg²⁺) salt.
54. The compound according to any one of claims 1-46, which is in form of a hydrochloride salt.
55. The compound according to claim 54, wherein the compound is in form of a mono hydrochloride salt.
 56. The compound according to claim 54, wherein the compound is in form of a bis-hydrochloride salt.
55. The compound according to claim 54, wherein the compound is in form of a tris-hydrochloride salt.
56. The compound according to claim 1, which is 4-(1H-imidazol-2-yl)-2-methyl-5-(morpholinomethyl)pyridin-3-ol hydrochloride, 4-(1H-imidazol-2-yl)-2-methyl-5-(morpholinomethyl)pyridin-3-ol bishydrochloride, 4-(1H-imidazol-2-yl)-2-methyl-5-(morpholinomethyl)pyridin-3-ol trishydrochloride, 5-(azepan-1-ylmethyl)-4-(1H-imidazol-2-yl)-2-methylpyridin-3-ol hydrochloride, or methyl 1-((5-hydroxy-4-(1H-imidazol-2-yl)-6-methylpyridin-3-yl)methyl)azetidine-3-carboxylate hydrochloride.
57. The compound according to any of claims 1-56, which is in isotopically enriched form.
58. The compound according to any of claims 1-56, which is in isotopically ¹⁵N enriched form.
59. A pharmaceutical composition comprising the compound of any of claims 1-58 and a pharmaceutically acceptable carrier.
60. A method for treating or inhibiting development of one or more AGE- and/or ALE-associated complications in subject in need thereof comprising administering one or more compounds according to any of claims 1-58 or one or more pharmaceutical compositions according to claim 59 to the subject.
61. The method of claim 60 wherein the one or more AGE- and/or ALE-associated complications are selected from the group consisting of accelerated protein aging, retinopathy, nephropathy, proteinuria, impaired glomerular clearance, neuropathy, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, atherosclerosis, cardiovascular disease, neurodegenerative amyloid diseases, diabetes-associated hyperlipidemia, oxidative modification of proteins, arthritis, connective tissue diseases, amyloidosis, obesity-related complications, proliferation of smooth muscle cells in the aorta, coronary artery occlusion, hypertension; and dialysis-related disorders selected from the group consisting of dialysis-related cardiac morbidity and mortality, dialysis-related amyloidosis, dialysis-related increases in permeability of the peritoneal membrane in a dialysis patient, renal failure progression in a dialysis patient, and ultrafiltration failure and peritoneal membrane destruction in a dialysis patient.
 62. A method for treating or inhibiting development of one or more disorders selected from the group consisting of diabetic nephropathy, proteinuria, impaired glomerular clearance, retinopathy, neuropathy, atherosclerosis, diabetes-associated hyperlipidemia, oxidative modification of proteins, arthritis, connective tissue diseases, amyloidosis, obesity-related complications proliferation or smooth muscle cells in the aorta, coronary artery occlusion, and hypertension; and dialysis-related disorders including dialysis-related cardiac morbidity and mortality, dialysis-related amyloidosis, dialysis-related increases in permeability of the peritoneal membrane in a dialysis patient, renal failure progression in a dialysis patient, and inhibiting ultrafiltration failure and peritoneal membrane destruction in a dialysis patient, wherein the method comprises administering an effective amount of a one or more compounds according to any of claims 1-58 or one or more pharmaceutical compositions according to claim 59 to a subject in need of such treatment..
